HemaTerra introduces scheduling system for blood clinics, hospitals

HemaTerra Technologies, Jacksonville, Florida-based providers of software to healthcare facilities handling blood and other biologic products, has launched HemaComply–Equipment Manager, a quality control scheduling system made especially for facilities that handle blood.

The maintenance of lab and medical equipment requires time to properly update calibration schedules for the large amount of equipment. The HemaComply-Equipment Manager takes over the roles of scheduling, documentation and review of preventative measures and supports.

By scheduling all equipment in a single system, the manager is able to keep equipment in check with specifications, therefore maintaining compliance throughout a facility. The system also includes multiple features such as order entry, inventory management and product quality control, giving clinicians the ability to identify issues within the systems at a faster pace.

"Our partners discussed their challenges with other equipment management systems and believe those challenges were amplified by using software that is antiquated in both design and direction. Also, that the software does not integrate with existing systems in the blood center's ecosystem,” said Todd Collins, president and CEO of HemaTerra Technologies. “What makes our product unique is that we are investing the time and resources to fully integrate this product with their usage of HemaConnect, HemaControl and HemaComply–QC. In other words, a piece of equipment taken out of service prompts an appropriate reaction within their donor recruitment, order entry, inventory management and QC areas."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.